Literature DB >> 17238482

Ad hoc versus standardized admixtures for continuous infusion drugs in neonatal intensive care: cognitive task analysis of safety at the bedside.

Timothy S Brannon1.   

Abstract

Continuous infusion intravenous (IV) drugs in neonatal intensive care are usually prepared based on patient weight so that the dose is readable as a simple multiple of the infusion pump rate. New safety guidelines propose that hospitals switch to using standardized admixtures of these drugs to prevent calculation errors during ad hoc preparation. Extended hierarchical task analysis suggests that switching to standardized admixtures may lead to more errors in programming the pump at the bedside.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17238482      PMCID: PMC1839298     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  4 in total

1.  An extended hierarchical task analysis for error prediction in medical devices.

Authors:  Phillip H Chung; Jiajie Zhang; Todd R Johnson; Vimla L Patel
Journal:  AMIA Annu Symp Proc       Date:  2003

2.  JCAHO's compliance expectations for standardized concentrations. Rule of Six in pediatrics does not meet requirements.

Authors: 
Journal:  Jt Comm Perspect       Date:  2004-05

3.  A controlled trial of smart infusion pumps to improve medication safety in critically ill patients.

Authors:  Jeffrey M Rothschild; Carol A Keohane; E Francis Cook; E John Orav; Elisabeth Burdick; Sarah Thompson; Judy Hayes; David W Bates
Journal:  Crit Care Med       Date:  2005-03       Impact factor: 7.598

4.  Design of a safer approach to intravenous drug infusions: failure mode effects analysis.

Authors:  M Apkon; J Leonard; L Probst; L DeLizio; R Vitale
Journal:  Qual Saf Health Care       Date:  2004-08
  4 in total
  1 in total

1.  Clinical data needs in the neonatal intensive care unit electronic medical record.

Authors:  Marc A Ellsworth; Tara R Lang; Brian W Pickering; Vitaly Herasevich
Journal:  BMC Med Inform Decis Mak       Date:  2014-10-24       Impact factor: 2.796

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.